Business
Vedanta Prevails in Important EU Patent Opposition
Vedanta Prevails in Important EU Patent Opposition.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \nRNS Number : 1162Y PureTech Health PLC 07 May 2019 \n\n7 May 2019\n \nPureTech Health plc\n \nPureTech's Vedanta Biosciences Announces Favourable Decision for Key Microbiome Patent\n \nEuropean Patent Office decision further solidifies Vedanta's leading IP position in the microbiome therapeutic field\n \nPureTech Health plc (LSE:PRTC) (\"PureTech Health\"), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis, is pleased to announce that the European Patent Office has issued a decision to uphold Vedanta Bioscience's foundational patent EP2575835 (the \"Honda patent\"). This patent covers compositions of clostridial bacterial species for use in infectious and allergic disease, and is based on groundbreaking work by Dr Kenya Honda, a scientific co-founder of Vedanta Biosciences. The Honda patent is exclusively licensed to Vedanta under an agreement with the University of Tokyo and provides coverage through at least 2031.\n \nThis decision reinforces Vedanta's leadership position in the microbiome field as clostridial species are abundant in the gut and due to their immunomodulatory potential are of core interest for use in the development of live biotherapeutic products designed to colonise and modulate a patient's microbiome to therapeutic effect.\n \nBharatt Chowrira, JD, PhD, president and chief of business and strategy at PureTech Health, said: \"In an emerging field as novel as microbiome therapies, capturing the value of groundbreaking discoveries is crucial to build a long-term foundation for IP leadership. Vedanta has always ensured its broad platform for therapeutic discovery and development has been supported by a strategic and comprehensive intellectual property portfolio, so this decision reflects both that long-term strategy and the truly novel contributions of Dr Honda.\"\n \nThe full text announcement from Vedanta is as follows:\n \nVedanta Biosciences Key Microbiome Patent Upheld in European Opposition Proceedings \nUpheld patent EP2575835 covers therapeutic compositions of clostridial bacterial species derived from the human microbiome \nDecision further solidifies Vedanta's leading IP position in the microbiome therapeutic field\nCAMBRIDGE, Mass., May 7, 2019 - Vedanta Biosciences, a clinical-stage c...